

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Scoping

STA Semaglutide for managing overweight and obesity [ID3850]

Batch 76

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop), and, if so, what are they?

The following issues were raised during the scoping consultation:

- Socioeconomic status influences the incidence and impact of obesity.
- There is inequality in the access to treatment due to the availability of obesity services throughout England.
- The body mass index (BMI) threshold for treatment should be lower for members of minority ethnic groups known to be at equivalent risk of the consequences of obesity at a lower BMI than the white population.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

Where appropriate, the committee will consider the equalities issues raised. Issues related to incidence of a disease and implementation regarding access to services cannot be addressed in a technology appraisal. The committee will consider whether changes to BMI thresholds for members of particular minority ethnic groups are appropriate in any recommendations it makes.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes to the matrix been made?

No.

Approved by Associate Director (name):Janet Robertson.....

Date: 14 May 2021